A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2022-12-17
Adverse events
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-01-17 (study day 22); relationship: not assessed
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-02-03 (study day 39); relationship: not assessed
Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-06-15 (study day 171); relationship: not assessed
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-06-21 (study day 177); relationship: not assessed
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-07-15 (study day 201); relationship: not assessed
Grade 3 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-10-07 (study day 285); relationship: N
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-11-04 (study day 313); relationship: Y
Grade 1 Nausea — outcome: UNKNOWN; onset 2024-01-19 (study day 389); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2024-05-18 (study day 509); relationship: not assessed
Data queries
No data queries.